Literature DB >> 6131996

Binding of several phenothiazine neuroleptics to a common binding site of alpha 1-acid glycoprotein, orosomucoid.

S El-Gamal, U Wollert, W E Müller.   

Abstract

The interaction of several phenothiazine neuroleptics with alpha 1-acid glycoprotein was investigated using circular dichroism and equilibrium dialysis techniques. For chlorpromazine only, one high-affinity binding site of the protein was found. The binding of the drug to this single site generated typical polyphasic extrinsic Cotton effects. Since several other phenothiazine neuroleptics gave qualitatively comparable extrinsic Cotton effects in the presence of alpha 1-acid glycoprotein and potently inhibited the binding of chlorpromazine to the single site, it was concluded that all phenothiazine derivatives investigated bound preferentially to only one common binding site of the alpha 1-acid glycoprotein molecule.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6131996     DOI: 10.1002/jps.2600720229

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  Drug binding to alpha 1-acid glycoprotein studied by circular dichroism.

Authors:  M Otagiri; R Yamamichi; T Maruyama; T Imai; A Suenaga; Y Imamura; K Kimachi
Journal:  Pharm Res       Date:  1989-02       Impact factor: 4.200

2.  Fluorescence quenching of human orosomucoid. Accessibility to drugs and small quenching agents.

Authors:  M L Friedman; K T Schlueter; T L Kirley; H B Halsall
Journal:  Biochem J       Date:  1985-12-15       Impact factor: 3.857

3.  The biotransformation of thioridazine to thioridazine 5-sulfoxide stereoisomers in phenobarbital induced rats.

Authors:  P W Hale; A Poklis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Oct-Dec       Impact factor: 2.441

4.  Characterization of a common binding site for basic drugs on human alpha 1-acid glycoprotein (orosomucoid).

Authors:  W E Müller; A E Stillbauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-03       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.